Improving the understanding of how patients with non-dystrophic myotonia are selected for myotonia treatment with mexiletine (NaMuscla): outcomes of treatment impact using a European Delphi panel

Table 3 Frequency of resource use per patient with NDM per year in the UK^a

Health resource	Round 1 (n = 5, 1 drop-out)				Round 2 (n = 4, 1 drop-out)
Health resource	BSC – Mean number of annual visits (range)	Mexiletine – Mean number of annual visits (range)	Difference (%)	BSC:mexiletine ratio^b	% Agreement that HRU is on average lower for patients treated with mexiletine among panel (% agreement among responders)
Physiotherapy	5.0 (2–9)	4.0 (0–9)	−1.0	1.3	60% (75%)
Occupational therapist	2.2 (1–5)	1.2 (0–4)	−1.0	1.8	60% (75%)
Speech therapy	1.2 (0–5)	0.4 (0–2)	−0.8	3.0	40% (50%)
Day case attendances	1.0 (0–2)	0.8 (0–2)	−0.2	1.3	40% (50%)
Overall BSC:mexiletine (NaMuscla) ratio				1.8	60% (75%)

Key: BSC Best supportive care (defined as any supportive care that symptomatic adult patients with NDM may receive that does not involve symptom-modifying pharmacological treatment; includes, for example, the use of supportive medication [e.g. pain killers], mobility aids, physiotherapy or speech therapy), HRU Healthcare resource utilization, NDM Non-dystrophic myotonia
^aPlease note that mobility aids are not included in this table as it was assumed that patients requiring this resource would only need one walking frame, wheelchair and/or walking stick per year
^bThe ratio was calculated by dividing the mean number of annual visits of patients receiving BSC that require a resource by the mean number of annual visits of patients treated with mexiletine (NaMuscla) that require the resource

ISSN: 1471-2377